clofazimine has been researched along with Bacteremia in 13 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL)." | 9.09 | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. ( Dubé, MP; Havlir, DV; Kemper, CA; Leedom, JM; McCutchan, JA; Sattler, FR; See, D; Tilles, JG; Torriani, FJ, 1999) |
| " avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group)." | 9.08 | A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. ( Fanning, MM; Fong, IW; Gill, MJ; Lalonde, RG; Phillips, P; Rachlis, AR; Salit, I; Shafran, SD; Singer, J; Tsoukas, CM; Walmsley, SL; Zarowny, DP, 1996) |
| "The individual antibacterial activities of clofazimine, ethambutol, and rifampin in the treatment of Mycobacterium avium complex bacteremia in patients with AIDS were determined." | 9.07 | The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. ( Bartok, AE; Dubé, M; Haghighat, D; Havlir, D; Kemper, CA; Leedom, JM; Sison, JP; Tilles, JG; Yangco, B; Yao, Y, 1994) |
| "A rapid reduction in symptoms and bacteremia can be achieved as early as week 2 of therapy using an oral regimen of rifampin, ethambutol, clofazimine, and ciprofloxacin." | 9.07 | Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. ( Bartok, AE; Chiu, J; Deresinski, SC; Feigal, DF; Kemper, CA; Leedom, JM; McCutchan, JA; Meng, TC; Nussbaum, J; Tilles, JG, 1992) |
| "During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL)." | 5.09 | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. ( Dubé, MP; Havlir, DV; Kemper, CA; Leedom, JM; McCutchan, JA; Sattler, FR; See, D; Tilles, JG; Torriani, FJ, 1999) |
| " avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group)." | 5.08 | A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. ( Fanning, MM; Fong, IW; Gill, MJ; Lalonde, RG; Phillips, P; Rachlis, AR; Salit, I; Shafran, SD; Singer, J; Tsoukas, CM; Walmsley, SL; Zarowny, DP, 1996) |
| "We conducted a randomized, open-label trial in 42 French hospitals to compare the clinical and bacteriologic efficacy of combination therapy with clarithromycin/clofazimine (Clm/Clof) with that of combination therapy with clarithromycin/rifabutin/ethambutol (Clm/Rib/Eth) as treatment for Mycobacterium avium bacteremia." | 5.08 | Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. ( Beuscart, C; Brel, F; Dautzenberg, B; Doco-Lecompte, T; Grosset, J; May, T; Perronne, C; Saint-Marc, T; Vincent, V, 1997) |
| " a placebo, each in combination with clofazimine and ethambutol, for the treatment of MAC bacteremia." | 5.07 | Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group. ( Gordin, FM; Sullam, PM; Wynne, BA, 1994) |
| "The individual antibacterial activities of clofazimine, ethambutol, and rifampin in the treatment of Mycobacterium avium complex bacteremia in patients with AIDS were determined." | 5.07 | The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. ( Bartok, AE; Dubé, M; Haghighat, D; Havlir, D; Kemper, CA; Leedom, JM; Sison, JP; Tilles, JG; Yangco, B; Yao, Y, 1994) |
| "A rapid reduction in symptoms and bacteremia can be achieved as early as week 2 of therapy using an oral regimen of rifampin, ethambutol, clofazimine, and ciprofloxacin." | 5.07 | Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. ( Bartok, AE; Chiu, J; Deresinski, SC; Feigal, DF; Kemper, CA; Leedom, JM; McCutchan, JA; Meng, TC; Nussbaum, J; Tilles, JG, 1992) |
| " The following areas were emphasized at the conference: multiresistant gram-positive bacteremias in patients with serious underlying infections, azithromycin's effectiveness against acute community-acquired pneumonia, results of clarithromycin plus ethambutol in HIV-infected patients with MAC bacteremia, duodenal ulcers associated with Helicobacter pylori infections, and use of roxithromycin against AIDS-related cryptosporidium diarrhea." | 3.69 | Macrolides, azalides, and streptogrammins. ( Prescott, LM, 1996) |
| "Amikacin was well tolerated." | 2.69 | A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team. ( Barber, TW; Currier, J; Ellner, JJ; Hafner, R; Hojczyk, P; Hooton, TM; Jacobs, MR; Limjoco, M; Parenti, DM; Powderly, WG; Simpson, G; van der Horst, C; Williams, PL, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (92.31) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sullam, PM | 1 |
| Gordin, FM | 1 |
| Wynne, BA | 1 |
| Kemper, CA | 5 |
| Havlir, D | 2 |
| Haghighat, D | 1 |
| Dubé, M | 1 |
| Bartok, AE | 3 |
| Sison, JP | 2 |
| Yao, Y | 2 |
| Yangco, B | 1 |
| Leedom, JM | 3 |
| Tilles, JG | 3 |
| Kane, C | 1 |
| Camp, B | 1 |
| Lane, N | 1 |
| Deresinski, SC | 3 |
| Hamilton, JR | 1 |
| Brummer, E | 1 |
| Stevens, DA | 1 |
| Shafran, SD | 2 |
| Singer, J | 2 |
| Zarowny, DP | 1 |
| Phillips, P | 1 |
| Salit, I | 2 |
| Walmsley, SL | 1 |
| Fong, IW | 1 |
| Gill, MJ | 1 |
| Rachlis, AR | 1 |
| Lalonde, RG | 1 |
| Fanning, MM | 1 |
| Tsoukas, CM | 2 |
| May, T | 1 |
| Brel, F | 1 |
| Beuscart, C | 1 |
| Vincent, V | 2 |
| Perronne, C | 1 |
| Doco-Lecompte, T | 1 |
| Saint-Marc, T | 1 |
| Dautzenberg, B | 1 |
| Grosset, J | 1 |
| Alfandari, S | 1 |
| Chidiac, C | 1 |
| Guery, B | 1 |
| Senneville, E | 1 |
| Mouton, Y | 1 |
| Vinocour, D | 1 |
| Parenti, DM | 1 |
| Williams, PL | 1 |
| Hafner, R | 1 |
| Jacobs, MR | 1 |
| Hojczyk, P | 1 |
| Hooton, TM | 1 |
| Barber, TW | 1 |
| Simpson, G | 1 |
| van der Horst, C | 1 |
| Currier, J | 1 |
| Powderly, WG | 1 |
| Limjoco, M | 1 |
| Ellner, JJ | 1 |
| Dubé, MP | 1 |
| Torriani, FJ | 1 |
| See, D | 1 |
| Havlir, DV | 1 |
| McCutchan, JA | 2 |
| Sattler, FR | 1 |
| Fournier, S | 1 |
| Burguière, AM | 1 |
| Flahault, A | 1 |
| Treilhou, MP | 1 |
| Eliaszewicz, M | 1 |
| Thorne, A | 1 |
| Khorasheh, S | 1 |
| Raboud, JM | 1 |
| Wu, AW | 1 |
| Lemieux, C | 1 |
| Prescott, LM | 1 |
| Meng, TC | 1 |
| Nussbaum, J | 1 |
| Chiu, J | 1 |
| Feigal, DF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.[NCT00000641] | Phase 2 | 90 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 trials available for clofazimine and Bacteremia
| Article | Year |
|---|---|
Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Bacteremia; Clofazimine; | 1994 |
The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Bacteremia; Clofazimine; Ethambutol; Femal | 1994 |
Transient bacteremia due to Mycobacterium avium complex in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Bacteremia; Clofazimine; Drug Therapy, Combination; Et | 1994 |
Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans?
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Bacteremi | 1996 |
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Bacterem | 1996 |
Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida.
Topics: Adult; AIDS-Related Opportunistic Infections; Bacteremia; Clarithromycin; Clofazimine; Drug Therapy, | 1997 |
A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team.
Topics: Adult; AIDS-Related Opportunistic Infections; Amikacin; Bacteremia; Ciprofloxacin; Clofazimine; Colo | 1998 |
Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group.
Topics: AIDS-Related Opportunistic Infections; Bacteremia; Ciprofloxacin; Clarithromycin; Clofazimine; Drug | 1999 |
Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients.
Topics: Aged; AIDS-Related Opportunistic Infections; Anti-Inflammatory Agents, Non-Steroidal; Bacteremia; Cl | 1999 |
Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Bacteremia; Canada; | 2000 |
Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Amikacin; Anti-Infective Agents; Ba | 1992 |
2 other studies available for clofazimine and Bacteremia
| Article | Year |
|---|---|
Pulmonary clofazimine crystals in two patients with the acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Bacteremia; Bronchoalveolar Lav | 1997 |
Macrolides, azalides, and streptogrammins.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; B | 1996 |